Recently, the National Medical Products Administration has conditionally approved the market registration application of GV-971 for mild to moderate Alzheimer's disease (hereinafter referred to as AD ) to improve patients' cognitive function.The drug was jointly developed by Ocean University of China, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Shanghai Green Valley Pharmaceutical Co., Ltd. It is a low-molecular acid oligosaccharide compound obtained by using marine brown algae extract as a raw material. It is an innovative drug independently researched and developed by China with independent intellectual property rights. The successful marketing of this drug fills the gap of 17 years in the field of anti-AD and will benefit tens of millions of AD patients and families.
GV-971 was developed by Ocean University of China in 1997. After 22 years of development, GV-971 was finally successful. Since 1997, the team led by academician Guan Huashi of Ocean University of China has proposed, discovered and confirmed the value of 971 lead in the treatment of AD, and carried out systematic drug-making research work such as pharmacy, pharmacodynamics, and safety evaluation. The 971 candidate drug was launched into clinical research in 2006, and the first phase clinical trial was successfully completed, and it was successfully promoted to the second phase clinical trial. After that, researcher Geng Meiyu from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, led a team of researchers from Shanghai Green Valley Pharmaceutical and Shanghai Institute of Materia Medica, who played an important role and made outstanding contributions in the follow-up clinical research and mechanism research of 971. As a new marine drug jointly developed by the three units, 971 is the result of concerted efforts and collaborative innovation by all parties, and is the result of collaborative research and win-win cooperation among universities-research institutes-enterprises.
This has a strong demonstration significance for the construction and improvement of the collaborative innovation mechanism from discovery, research and development to marketing of original new drugs in China.
The successful marketing of GV-971 greatly improves the development ability of original new drugs in China, also marks the great potential of the development of Blue pharmacy. It is believed that in the context of the new era of the in-depth implementation of the strategy of a marine power and a healthy China, more and more original marine scientific and technological achievements will usher in bursts of output, which will greatly benefit society.
Text source: Guanhai Tingtao
【Close】
